AI Engines For more Details: Perplexity Kagi Labs You
Schizophrenia: Fluspirilene is effective in managing the symptoms of schizophrenia, a chronic mental disorder characterized by distorted thinking, hallucinations, delusions, disorganized speech, and impaired social functioning. It helps alleviate positive symptoms (such as hallucinations and delusions) and negative symptoms (such as social withdrawal and apathy) associated with schizophrenia. Fluspirilene belongs to the class of medications known as typical or first-generation antipsychotics, which work by blocking dopamine receptors in the brain, thereby reducing the activity of dopamine, a neurotransmitter implicated in the pathophysiology of schizophrenia.
Psychotic Disorders: In addition to schizophrenia, fluspirilene may be used in the management of other psychotic disorders, including schizoaffective disorder, psychotic depression, and bipolar disorder with psychotic features. It helps stabilize mood, improve cognitive function, and reduce the severity of psychotic symptoms in patients experiencing acute episodes or chronic relapses of these conditions.
Maintenance Therapy: Fluspirilene can be prescribed for long-term maintenance therapy to prevent the recurrence of psychotic symptoms and minimize the risk of relapse in patients with schizophrenia or related psychotic disorders. It is often used in conjunction with psychosocial interventions, such as supportive therapy, cognitive-behavioral therapy, and vocational rehabilitation, to optimize treatment outcomes and promote recovery in individuals with persistent mental illness.
Dosage Forms: Fluspirilene is available in various formulations for oral and injectable administration. The oral formulation may be in the form of tablets or liquid concentrate, while the injectable formulation is typically administered as a long-acting depot injection, providing sustained release of the medication over an extended period. The choice of dosage form depends on factors such as the patient's clinical status, treatment response, and preferences, as well as the healthcare provider's recommendations.
Side Effects: Like other antipsychotic medications, fluspirilene may cause a range of side effects, including extrapyramidal symptoms (such as tremors, muscle stiffness, and abnormal movements), sedation, drowsiness, dizziness, orthostatic hypotension (drop in blood pressure upon standing), weight gain, metabolic disturbances (such as hyperglycemia and dyslipidemia), anticholinergic effects (such as dry mouth, constipation, and urinary retention), and hormonal imbalances (such as hyperprolactinemia). Rare but potentially serious adverse effects may include neuroleptic malignant syndrome (NMS), tardive dyskinesia (involuntary movements), and QT prolongation (a heart rhythm disorder). Patients should be monitored regularly for adverse effects during treatment with fluspirilene, and dose adjustments or alternative medications may be considered if side effects occur or worsen over time.
Drug Interactions: Fluspirilene may interact with other medications, particularly those that affect the central nervous system (CNS) or prolong the QT interval, increasing the risk of adverse effects or reducing the efficacy of treatment. Patients should inform their healthcare providers about all prescription drugs, over-the-counter medications, vitamins, and herbal supplements they are taking before starting fluspirilene therapy to minimize the risk of drug interactions and potential complications.
Contraindications: Fluspirilene is contraindicated in patients with known hypersensitivity to the drug or its components and in individuals with a history of QT prolongation, ventricular arrhythmias, or other significant cardiac abnormalities. It should be used with caution in patients with preexisting medical conditions, such as cardiovascular disease, diabetes, epilepsy, or liver impairment, as well as in elderly patients or those at increased risk of falls or aspiration.
Monitoring and Follow-up: Patients receiving fluspirilene therapy should undergo regular monitoring of vital signs, weight, metabolic parameters (including fasting blood glucose, lipid profile, and body mass index), and electrocardiograms (ECGs) to assess treatment response, detect potential side effects, and ensure patient safety. Close collaboration between the patient, psychiatrist, and other healthcare providers is essential to optimize the management of schizophrenia and promote the overall well-being of individuals with mental illness.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
ADHD | 2.2 | 0.3 | 6.33 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 2.3 | 0.6 | 2.83 |
Allergies | 2.2 | 0.9 | 1.44 |
Allergy to milk products | 0.8 | 1.3 | -0.63 |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 2.8 | 5.3 | -0.89 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.2 | 7.5 |
Ankylosing spondylitis | 2.3 | 1.3 | 0.77 |
Anorexia Nervosa | 0.7 | 2.3 | -2.29 |
Antiphospholipid syndrome (APS) | 1.3 | 0.3 | 3.33 |
Asthma | 2.2 | 1.1 | 1 |
Atherosclerosis | 1.1 | 1.1 | 0 |
Atrial fibrillation | 2.5 | 2.8 | -0.12 |
Autism | 5.6 | 6 | -0.07 |
Autoimmune Disease | 0.9 | 0.5 | 0.8 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.3 | 1.3 | |
Bipolar Disorder | 1.6 | 0.8 | 1 |
Brain Trauma | 0.3 | 0.8 | -1.67 |
Breast Cancer | 0.2 | 0.2 | |
Carcinoma | 1.9 | 0.7 | 1.71 |
Celiac Disease | 2.7 | 1.3 | 1.08 |
Cerebral Palsy | 0.6 | 0.8 | -0.33 |
Chronic Fatigue Syndrome | 2.2 | 3 | -0.36 |
Chronic Kidney Disease | 2.5 | 2.2 | 0.14 |
Chronic Lyme | 0.4 | 0.8 | -1 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.4 | -0.56 |
Chronic Urticaria (Hives) | 1.1 | 1.2 | -0.09 |
Coagulation / Micro clot triggering bacteria | 1.5 | 0.8 | 0.88 |
Cognitive Function | 1 | 0.8 | 0.25 |
Colorectal Cancer | 4.3 | 1.6 | 1.69 |
Constipation | 1.9 | 0.5 | 2.8 |
Coronary artery disease | 2 | 2.3 | -0.15 |
COVID-19 | 3.3 | 5.9 | -0.79 |
Crohn's Disease | 5.6 | 3.3 | 0.7 |
Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
cystic fibrosis | 0.8 | 0.8 | 0 |
d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
deep vein thrombosis | 1.7 | 1.1 | 0.55 |
Denture Wearers Oral Shifts | 0.3 | 0.3 | |
Depression | 5.4 | 5.4 | 0 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.6 | 0.9 | 0.78 |
Endometriosis | 2.1 | 1.3 | 0.62 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 2 | 0.7 | 1.86 |
erectile dysfunction | 0.9 | 0.9 | |
Fibromyalgia | 1 | 2.1 | -1.1 |
Functional constipation / chronic idiopathic constipation | 4.3 | 2.9 | 0.48 |
gallstone disease (gsd) | 2.5 | 0.5 | 4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.6 | 1.17 |
Generalized anxiety disorder | 2.3 | 0.9 | 1.56 |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.6 | 0.3 | 1 |
Graves' disease | 0.7 | 1.4 | -1 |
Gulf War Syndrome | 0.6 | 0.8 | -0.33 |
Halitosis | 0.6 | 0.3 | 1 |
Hashimoto's thyroiditis | 1.6 | 1 | 0.6 |
Heart Failure | 3.4 | 1.1 | 2.09 |
hemorrhagic stroke | 0.4 | 0.4 | |
Hidradenitis Suppurativa | 1.2 | 1.2 | |
High Histamine/low DAO | 0.7 | 0.7 | |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.8 | 0.7 | 0.14 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 2 | 3.4 | -0.7 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 1 | 2.9 | -1.9 |
Inflammatory Bowel Disease | 4.7 | 4.9 | -0.04 |
Insomnia | 0.9 | 1.7 | -0.89 |
Intelligence | 1.4 | 0.6 | 1.33 |
Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
Irritable Bowel Syndrome | 3.6 | 3.4 | 0.06 |
ischemic stroke | 1.2 | 1.7 | -0.42 |
Liver Cirrhosis | 4.4 | 1.9 | 1.32 |
Long COVID | 4.5 | 2.9 | 0.55 |
Low bone mineral density | 1.1 | -1.1 | |
Lung Cancer | 0.9 | 0.9 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
ME/CFS with IBS | 0.4 | 0.9 | -1.25 |
ME/CFS without IBS | 1 | 0.4 | 1.5 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.3 | 0.5 | -0.67 |
Metabolic Syndrome | 4.4 | 4.6 | -0.05 |
Mood Disorders | 4.5 | 4.2 | 0.07 |
multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
Multiple Sclerosis | 2.4 | 3.9 | -0.63 |
Multiple system atrophy (MSA) | 0.7 | 0.7 | |
myasthenia gravis | 0.9 | 0.5 | 0.8 |
neuropathic pain | 2.2 | -2.2 | |
Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.8 | 2 | 0.4 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 5.2 | 3.4 | 0.53 |
obsessive-compulsive disorder | 4.3 | 2.6 | 0.65 |
Osteoarthritis | 2.4 | 0.6 | 3 |
Osteoporosis | 1.4 | 0.6 | 1.33 |
pancreatic cancer | 0.3 | 0.3 | 0 |
Parkinson's Disease | 4 | 5.1 | -0.27 |
Polycystic ovary syndrome | 4.5 | 1.4 | 2.21 |
Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.3 | 0.9 | -2 |
Primary sclerosing cholangitis | 1.1 | 1.5 | -0.36 |
Psoriasis | 1.1 | 2.8 | -1.55 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.3 | 2.3 | 0.87 |
Rosacea | 0.1 | 0.5 | -4 |
Schizophrenia | 2.5 | 1.8 | 0.39 |
scoliosis | 0.5 | 0.5 | 0 |
Sjögren syndrome | 1.9 | 1.6 | 0.19 |
Sleep Apnea | 0.6 | 1.1 | -0.83 |
Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
Stress / posttraumatic stress disorder | 1.5 | 1.6 | -0.07 |
Systemic Lupus Erythematosus | 3.5 | 0.9 | 2.89 |
Tic Disorder | 1 | 0.6 | 0.67 |
Tourette syndrome | 0.3 | 0.3 | 0 |
Type 1 Diabetes | 3 | 2.1 | 0.43 |
Type 2 Diabetes | 5.6 | 4.2 | 0.33 |
Ulcerative colitis | 3.4 | 5.5 | -0.62 |
Unhealthy Ageing | 3.7 | 1.9 | 0.95 |
Vitiligo | 1.9 | 1 | 0.9 |